Malaria is a severe disease associated with significant mortality, mainly attributed to *Plasmodium falciparum* and to delayed treatment [@bib1]. Patients with clinical criteria of severe disease should be hospitalized and aggressively treated with intravenous anti-parasite drugs. UK recommendations suggest treating intravenously as soon as the parasitaemia is above 2% [@bib2].

The correlation between parasitaemia and severity of disease is well established for quantification derived from microscopy [@bib3]. Correlation between clinical severity and DNA quantification by PCR in blood has already been demonstrated for other infections, such as *Streptococcus pneumoniae* [@bib4], *Staphylococcus aureus* [@bib5] or *Neisseria meningitidis* [@bib6], but the value of real-time PCR quantification to predict outcome is unknown for *P. falciparum* infection.

In our diagnostic laboratory, real-time Taqman PCR has been used to confirm species identification for every positive microscopy, as a systematic internal quality control since January 2004. This quantitative PCR targeting the 18S rRNA encoding gene [@bib7], has also been implemented in other diagnostic microbiology laboratories [@bib8; @bib9]. The objective of this work was to assess (among patients with single *P. falciparum* infection) whether parasitaemia determined by microscopy and/or PCR correlated with the clinical severity of malaria.

From 1 January 2004 to 31 December 2011, we included in our work all patients found infected by only *P. falciparum*, as determined by Giemsa-stained thin smear and by a multiplex PCR performed on their first EDTA--blood sample. The included patients were adults (\>16 years old) hospitalized at the University Hospital, Lausanne (Switzerland) or consulting at the Department of Ambulatory Care and Community Medicine of Lausanne\'s University Hospital. This project was approved by our local ethics committee.

For microscopy, parasitaemia was initially reported in %. The number of *P. falciparum* parasites per mL of blood was estimated assuming that 1 μL contains 5 × 10^6^ red blood cells. Hence, 1% parasitaemia corresponded to 50 000 parasites/μL of blood and to 50 000 000 parasites/mL. Quantification was then converted in log parasites/mL.

All samples positive for *P. falciparum* by direct microscopy were confirmed by a multiplex *Plasmodium* quantitative real-time PCR [@bib7], detecting the four most common human *Plasmodium* species (*P. falciparum*, *Plasmodium ovale*, *Plasmodium vivax* and *Plasmodium malariae*). Then, using the set of primers and probes specific for *P. falciparum*, we confirmed all positive results by a subsequent *P. falciparum* monoplex PCR to precisely quantify the number of parasite copies/mL of blood. Quantification was first expressed in number of DNA copies/mL and then converted in log copies/mL as described in Dormond et al. [@bib10].

Demographic (country of exposure) and clinical characteristics were retrospectively retrieved from clinical charts. Eight characteristics, following the WHO criteria of severe malaria [@bib1], were considered: (i) cerebral malaria (coma) or impairment of consciousness, (ii) adult respiratory distress syndrome or pulmonary oedema, (iii) haemostatic abnormalities (bleeding or disseminated intravascular coagulation), (iv) severe hypotension (\<70 mmHg of systolic blood pressure) or shock, (v) severe anaemia (haemoglobin \<50 g/L), (vi) acute renal failure (creatinine concentration \>265 μmol/L), (vii) jaundice (total serum bilirubin ≥50 μmol/L) and severe hypoglycaemia (\<2.2 mmol/L). Patients with one or more than one of these criteria were considered as severe malaria cases. The statistical analyses have been performed using the [GraphPad Prism]{.smallcaps} software 5.02 (GraphPad Software, La Jolla, CA, USA). Medians were compared using the Wilcoxon test.

The correlation between clinical severity and parasitaemia as well as PCR quantification was assessed for 112 patients with isolated *P. falciparum* infections confirmed by PCR. Most of those patients exhibited no criteria of severity (92/112; 82.1%) or one single criterion (11/112; 9.8%). Seven patients presented two criteria, one patient presented three criteria and one patient presented four criteria of severity. Neurological impairment and jaundice were the commonest observed criteria of severe malaria ([Table 1](#tbl1){ref-type="table"}). Notably, except for one patient who had returned from South America, all patients acquired *P. falciparum* infection in sub-Saharan Africa (60.0% in West Africa, 36.4% in Central Africa and 2.7% in East Africa).

As expected, parasitaemia estimated by microscopy significantly correlated with clinical severity ([Fig. 1](#fig1){ref-type="fig"}a). Parasitaemia was significantly higher among patients with at least one criterion of severe malaria (median of 7.63 log copies/mL; interquartile range (IQR) 7.00--8.39 log copies/mL) compared with patients with 0 severity criteria (median of 7.09 log copies/mL; IQR 5.70--7.74 log copies/mL; p \< 0.001). Moreover, both of the patients with at least three severity criteria exhibited a parasitaemia \>100 × 10^6^ parasites/mL (\>2%; log 8 parasites/mL).

A similar correlation between clinical severity and parasite load determined by PCR could be demonstrated ([Fig. 1](#fig1){ref-type="fig"}b). The number of *Plasmodium*-specific DNA copies/mL was significantly higher among patients with one or more severity criteria (median of 6.87 log copies/mL; IQR 5.87--7.73 log copies/mL) compared with patients with 0 severity criteria (median of 6.22 log copies/mL; IQR 5.17--6.94 log copies/mL; p \< 0.001). The number of plasmodial DNA copies was high, i.e. above 16 900 000 copies/mL (log 7 copies/mL), among both patients with at least three criteria of severe malaria. These two patients with at least three criteria of severe malaria both exhibited a parasitaemia ≥2%. This correlates with a previous study where patients with parasitaemia of ≥2% had an odds ratio of severe *P. falciparum* malaria that was 12-fold higher than in patients with \<2% parasitaemia [@bib11], and this threshold was proposed to decide on the choice of parenteral anti-malarials to administer [@bib2]. According to our results, when PCR is used for quantification, a threshold of parasitaemia of \>log 7 might be proposed for such a decision. Moreover, an added value of PCR quantification is also present for low DNA load, as all six patients with a parasitaemia of \<log 4 exhibited no criteria of severity. However, interpretation of quantitative PCR results should take into account the overall clinical presentation, as low parasitaemia has been reported in patients with severe malaria, due to splenic sequestration [@bib12], especially in non-immune patients. This \<log 4 cut-off should be challenged in future larger studies, because our work relies on a small number of patients and we observed a large dynamic range of parasitaemia among patients without criteria of severity. Practically, the quantitative PCR will not replace microscopy, which provides an earlier result and is available 24/24 and 7/7. The main advantage of having such an additional quantitative approach is for clinical studies [@bib10] and for specific cases, such as estimating the parasitaemia retrospectively in a dead patient when full blood is no longer available [@bib13].

In conclusion, we observed a significant correlation between first parasite load as determined by microscopy and the number of severity criteria. We also observed a significantly higher parasite load as determined by PCR in patients with at least one criterion of severe malaria compared with those without any criteria of severity. Hence, quantitative PCR might be useful to predict the outcome of patients with *P. falciparum* infection and to guide prescription of intravenous anti-malarial treatment.
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###### 

Criteria of severe malaria among 112 patients presenting single *Plasmodium falciparum* infection (20 patients presented at least one criteria of severe malaria)

  Criteria of severe malaria                                              Frequencies   
  ----------------------------------------------------------------------- ------------- -------
  Cerebral malaria (coma) or impairment of consciousness                  12/112        (11%)
  Jaundice (total serum bilirubin ≥50 μmol/L)                             8/112         (7%)
  Haemostatic abnormalities (bleeding or DIC)                             4/112         (4%)
  Severe hypotension (\<70 mmHg of systolic blood pressure)               4/112         (4%)
  Acute renal failure (creatinine concentration \>265 μmol/L)             2/112         (2%)
  ARDS or pulmonary oedema                                                2/112         (2%)
  Severe anaemia (haemoglobin \<50 g/L)                                   0/112         (0%)
  Severe hypoglycaemia (\<2.2 mmol/L)[a](#tbl1fna){ref-type="table-fn"}   0/112         (0%)

ARDS, adult respiratory distress syndrome; DIC, disseminated intravascular coagulation.

Information mainly available in severe cases.
